Blog

  • Arrive AI Announces Third Quarter 2025 Results, Continued Momentum on Strategic and Operating Milestones

    Arrive AI Announces Third Quarter 2025 Results, Continued Momentum on Strategic and Operating Milestones

    INDIANAPOLIS, IN / ACCESS Newswire / November 14, 2025 / Arrive AI (NASDAQ:ARAI), an autonomous delivery network anchored by patented AI-powered Arrive Points™, today announced its business results for the third quarter of 2025.

    Q3 2025 Key Highlights:

    • Team Expansion: Hired nearly 30 professionals during third quarter; year-end goal is 60 new hires across AI, software, and product engineering.

    • Autonomous Robotic Automation for Healthcare: In a first phase of work at Hancock Health, installed and began testing robotic delivery system, the first deployed fully asynchronous robotic automation for medical deliveries inside a hospital, aiming to generate significant cost savings and operational efficiencies. The deployment at Hancock Health is ongoing, where Arrive AI is optimizing robotic delivery of biospecimens, lab samples, and medications. Phase two involves linking Hancock’s 29 satellite facilities to the primary lab via drone.

    • Strategic Partnerships and Expansion: Expanded partnership with Skye Air Mobility in India for international module deployment. Signed new agreements with a diverse range of partners, including Synoptek and Ottonomy.

    • Strengthened Intellectual Property Leadership: Secured U.S. Patent Office protection for ninth Arrive Point patent, strengthening security by reducing ways units can be tampered with or damaged by weather or other impacts. This patent expands CEO Dan O’Toole’s foundational patent for the Arrive Point, the first device ever to win patent protection for a smart mailbox docking station housing, to not only include drones but also robots and humans.

    • Product development : Integrating AI-powered Time-of-Flight (TOF) sensors into Arrive Points to optimize pickup efficiency, lower energy use, and improve data analytics as part of the current Arrive Point (AP3)

    Q3 2025 Key Financial Results

    Revenue: $7,450. Recurring subscription revenue growth was increased with two new Arrive Points in service this quarter. At this early stage in the development of Arrive AI’s business, management expects quarterly fluctuations in revenue levels as customer agreements are secured, built out and ramped up over time.

    Net Loss: $2.2 million, compared to a loss of $0.8 million in the same quarter of 2024. Spending was kept to a minimum through strict cost management while still investing in future growth, with operating expenses approximately $1 million lower than planned in the quarter.

    Cash and short-term liquid investments: $2.7 million at quarter-end, an increase of $2.1 million from the end of the prior quarter. Proceeds from the capital line of $4 million were received in August. Nearly all the new capital facility is available for future growth.

    CEO Commentary

    “During the third quarter, we made solid progress along our 2025 strategic and operating roadmap, building out our talent pool, completing phase one work with Hancock Health, and broadening our roster of strategic partnerships,” said Arrive AI CEO Dan O’Toole. “These are important steps forward along our value-creation strategy. We aren’t simply building a product at Arrive AI. We are building a system that has the potential to solve a $440 billion infrastructure problem in the last inch and drives measurable returns by reducing carrier operating costs and eliminating failed deliveries.”

    O’Toole continued, “We look forward to coming changes in the U.S. regulatory environment that enable autonomous operations, particularly following the FAA’s proposed Beyond Visual Line of Sight (BVLOS) rule and Governor Braun’s Indiana Initiative for Drone Dominance Task Force. Arrive AI’s platform enables full chain-of-custody, tracking every delivery from arrival through authenticated retrieval, and our Arrive Points are equipped with climate-assist technology for sensitive goods like pharmaceuticals and grocery items, and they integrate with smart home and smart city systems. Collectively, these components form the nervous system of autonomous logistics, one that ensures packages arrive securely, intelligently and precisely where they’re needed, with the intention of operating within coming regulatory standards.”

    Arrive AI continues to focus on its strategy built on disciplined, intelligent growth, deploying capital to build a scalable and defensible business model for the long-term, with near-term focus on four key areas:

    1. Team Expansion: Continue executing plans to triple Arrive AI’s workforce, focusing on AI, engineering, and business development.

    2. Commercialization and Operational Excellence: Productizing AP3 units – patented Arrive Points – and ongoing AP5 development to drive scalability and cost efficiency

    3. IP and Partnerships: Expanding intellectual property moat and forging alliances with strategic partners that embed our technology into their operations.

    4. Building Recurring Revenue Model: Building a platform-as-a-service model where every installation, delivery, and data point captured drives recurring revenue.

    O’Toole said, “We are approaching several potential catalysts and, as we execute our strategic growth plan, are focused on initiatives we believe can enhance long-term, shareholder value.”

    THIRD QUARTER CONFERENCE CALL

    The company will host a conference call and webcast today at 9:30 AM Eastern Time to review its results and strategic progress. Please join the webcast live via this link: https://edge.media-server.com/mmc/p/82noxgwv. Webcast participants will be able to submit questions through the webcast portal. To submit a question, simply login through the website link and click “ask a question” located in the upper right-hand side of the menu bar. A replay of the call will be accessible at https://www.arriveai.com/investor-relations.

    -30-

    About Arrive AI

    Arrive AI’s patented Autonomous Last Mile (ALM) platform enables secure, efficient delivery to and from a smart, AI-powered mailbox, whether by drone, ground robot or human courier. The platform provides real-time tracking, smart logistics alerts and advanced chain of custody controls to support shippers, delivery services and autonomous networks. By combining artificial intelligence with autonomous technology, Arrive AI makes the exchange of goods between people, robots and drones frictionless and convenient. Its system integrates with smart home devices such as doorbells, lighting and security systems to streamline the entire last-mile delivery experience. Learn more at www.arriveai.com and via the company’s press kit.

    Media contact: Cheryl Reed, media@arriveai.com

    Investor Relations Contact: Alliance Advisors IR, ARAI.IR@allianceadvisors.com

    Cautionary Note Regarding Forward Looking Statements

    This news release and statements of Arrive AI’s management in connection with this news release or related events contain or may contain “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. In this context, forward-looking statements mean statements, including but not limited to statements related to the future regulatory environment applicable to Arrive AI, the prospects of hiring the desired talents, and building productive and profitable products or systems related to future events, which may impact our expected future business and financial performance, and often contain words such as “expects”, “anticipates”, “intends”, “plans”, “believes”, “potential”, “will”, “should”, “could”, “would”, “optimistic” or “may” and other words of similar meaning. These forward-looking statements are based on information available to us as of the date of this news release and represent management’s current views and assumptions. Forward-looking statements are not guarantees of future performance, events or results and involve significant known and unknown risks, uncertainties and other factors which may be beyond our control. Readers are cautioned not to place undue reliance on these forward-looking statements, which apply only as of the date of this news release. Potential investors should review Arrive AI’s filings with the United States Securities and Exchange Commission for more complete information, including the risk factors that may affect future results, which are available for review at www.sec.gov. Accordingly, forward-looking statements should not be relied upon as a predictor of actual results. We do not undertake to update our forward-looking statements to reflect events or circumstances that may arise after the date of this news release, except as required by law.

    CONDENSED FINANCIAL STATEMENTS
     ARRIVE AI INC.
    CONDENSED BALANCE SHEETS
    (Unaudited)

    September 30, 2025

    December 31, 2024
    ASSETS
    CURRENT ASSETS
    Cash

    $

    816,715

    $

    129,318
    Accounts receivable

    4,900

    –
    Prepaid expenses

    164,777

    55,867
    Deferred offering costs

    6,312,586

    427,898
    Investments at fair value

    1,918,995

    –
    Other current assets

    721

    4,179
    Total current assets

    9,218,694

    617,262
    LONG-TERM ASSETS
    Property and equipment, net

    152,915

    95,425
    Right of use assets – operating leases

    73,041

    –
    Patents, net

    272,914

    273,601
    Security deposit

    1,500

    1,500
    Long-term assets

    500,370

    370,526
    TOTAL ASSETS

    $

    9,719,064

    $

    987,788
    LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)
    CURRENT LIABILITIES
    Accounts payable

    $

    707,100

    $

    1,868,689
    Accrued liabilities

    205,398

    79,556
    Credit card payable

    8,574

    3,636
    Current portion of operating lease liability

    38,041

    –
    Convertible note payable, net of discount of $282,667 and issuance costs of $240,000

    4,002,333

    –
    Current portion of note payable

    8,982

    8,524
    Total current liabilities

    4,970,428

    1,960,405
    NONCURRENT LIABILITIES
    Noncurrent portion of operating lease liability

    35,000

    –
    Note payables, net of current portion

    3,763

    10,558
    Total liabilities

    5,009,191

    1,970,963
    STOCKHOLDERS’ EQUITY (DEFICIT)
    Common stock, $0.0002 par value, 200,000,000 shares authorized, 34,233,087 issued and 34,213,387 outstanding as at September 30, 2025, and 29,120,905 issued and outstanding at December 31, 2024

    6,845

    5,822
    Treasury stock, at cost, 19,700 and -0- shares as of September 30, 2025, and December 31, 2024, respectively

    (74,743

    )

    –
    Additional paid-in capital

    29,602,998

    14,984,561
    Subscription receivable

    –

    (53,003

    )
    Accumulated deficit

    (24,825,227

    )

    (15,920,555

    )
    Total stockholders’ equity (deficit)

    4,709,873

    (983,175

    )
    TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)

    $

    9,719,064

    $

    987,788

    ARRIVE AI INC.
    CONDENSED STATEMENTS OF OPERATIONS
    (Unaudited)

    Three Months

    Nine Months

    Ended September 30,

    Ended September 30,

    2025

    2024

    2025

    2024
    REVENUE

    $

    7,450

    $

    –

    $

    98,175

    $

    –
    OPERATING EXPENSES
    General and administrative

    1,370,347

    791,639

    7,551,884

    2,395,881
    Research and development

    179,854

    7,940

    564,585

    548,879
    Sales and marketing

    107,530

    28,414

    164,793

    281,160
    Total operating expenses

    1,657,731

    827,993

    8,281,262

    3,225,920
    OTHER INCOME (EXPENSES)
    Other income

    23,388

    5,434

    83,454

    29,523
    Interest expense and bank charges

    (580,021

    )

    (1,192

    )

    (775,410

    )

    (3,209

    )
    Realized gain on investments

    46,491

    –

    46,491

    –
    Unrealized loss on investments

    (76,120

    )

    –

    (76,120

    )

    –
    Total other income (expenses)

    (586,262

    )

    4,242

    (721,585

    )

    26,314
    NET LOSS BEFORE TAXES

    (2,236,543

    )

    (823,751

    )

    (8,904,672

    )

    (3,199,606

    )
    PROVISION FOR INCOME TAXES

    –

    –

    –

    –
    NET LOSS

    $

    (2,236,543

    )

    $

    (823,751

    )

    $

    (8,904,672

    )

    $

    (3,199,606

    )
    NET LOSS PER SHARE:
    Basic and diluted

    $

    (0.07

    )

    $

    (0.03

    )

    $

    (0.28

    )

    $

    (0.11

    )
    WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING:
    Basic and diluted

    33,241,510

    29,000,241

    31,515,121

    28,935,738

    ARRIVE AI INC.
    CONDENSED STATEMENTS OF CASH FLOWS
    For the Nine Months Ended September 30, 2025 and 2024 (Unaudited)

    2025

    2024
    CASH FLOWS FROM OPERATING ACTIVITIES
    Net loss

    $

    (8,904,672

    )

    $

    (3,199,606

    )
    Adjustments to reconcile net loss to net cash used in operating activities
    Stock-based compensation

    3,134,655

    880,120
    Depreciation and amortization

    31,048

    21,792
    Amortization of discount on convertible debt

    357,333

    –
    Amortization of issuance costs on convertible debt

    240,000

    –
    Realized gain on investments

    (46,491

    )

    –
    Unrealized depreciation on investments

    76,120

    –
    Changes in operating assets and liabilities
    (Increase) decrease in
    Accounts receivable

    (4,900

    )

    –
    Prepaid expenses

    (108,910

    )

    (63,407

    )
    Other current assets

    3,458

    –
    Increase (decrease) in
    Accounts payable

    43,148

    408,485
    Accrued liabilities

    125,842

    21,889
    Credit card payable

    4,938

    (28,720

    )
    Net cash used in operating activities

    (5,048,431

    )

    (1,959,447

    )
    CASH FLOWS FROM INVESTING ACTIVITIES
    Construction in progress

    (87,850

    )

    –
    Proceeds from sales of investments

    3,018,635

    –
    Purchase of investments

    (4,967,259

    )

    –
    Net cash used in investing activities

    (2,036,474

    )

    –
    CASH FLOWS FROM FINANCING ACTIVITIES
    Proceeds from sale of common stock, net

    448,056

    2,031,682
    Purchase of treasury stock

    (74,743

    )

    –
    Proceeds from the exercise of warrants, net

    573,896

    –
    Repayments of note payables

    (6,337

    )

    (5,914

    )
    Proceeds from issuance of convertible debt

    7,530,000

    –
    Deferred offering costs

    (698,570

    )

    (100,000

    )
    Net cash provided by financing activities

    7,772,302

    1,925,768
    NET INCREASE (DECREASE) IN CASH

    687,397

    (33,679

    )
    CASH, BEGINNING OF PERIOD

    129,318

    325,472
    CASH, END OF PERIOD

    $

    816,715

    $

    291,793
    SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
    Cash paid for:
    Interest

    $

    175,640

    $

    1,277
    Income taxes

    $

    –

    $

    –
    SUPPLEMENTAL DISCLOSURE OF NONCASH INFORMATION
    Common stock issued as payment of offering costs

    $

    6,927,869

    $

    –
    Common stock issued as settlement of legal expenses

    $

    1,204,737

    $

    –
    Conversion of notes payable to common stock

    $

    4,125,000

    $

    –
    Deferred offering costs recognized as additional paid-in capital

    $

    1,741,750

    $

    –
    Cashless exercise of stock options

    $

    9,269

    $

    –

    SOURCE: Arrive AI Inc.

    View the original press release on ACCESS Newswire

  • Horizon Kinetics Holding Corporation Reports Third Quarter Results

    Horizon Kinetics Holding Corporation Reports Third Quarter Results

    Highlights for the Quarter ended September 30, 2025:

    • Management and advisory fee revenue of $17.8 million for the quarter ended September 30, 2025, a 36% increase from the third quarter of 2024

    • Management and advisory fee revenue of $55.5 million for the nine months ended September 30, 2025, a 49% increase from the nine months ended September 30, 2024.

    • Net income attributable to Horizon Kinetics Holding Corporation of $7.2 million, or $0.39 per common share for the three months ended September 30, 2025

    • Operating income for the third quarter of 2025 was $2.9 million, an increase of $3.9 million from a $0.9 million loss during the third quarter of 2024

    • Assets under management (“AUM”) of $10.4 billion as of September 30, 2025, an increase of 5.2% from December 31, 2024 and 25% from September 30, 2024

    • Board of Directors declared a $0.106 per share dividend

    NEW YORK CITY, NEW YORK / ACCESS Newswire / November 13, 2025 / Horizon Kinetics Holding Corporation (the “Company” or “HKHC”) (OTCID: HKHC) reported financial results for the third quarter of 2025. The Company’s management and advisory fee revenue grew during the quarter and year-to-date period as compared to 2024 resulting from increases in AUM in its separately managed accounts, ETFs, mutual funds and private funds. These increases in AUM across each of the various products and strategies were largely driven by increases in the market value of Texas Pacific Land Corporation (“TPL”) and Grayscale Bitcoin Trust during 2024, which have resulted in higher monthly management fees throughout 2025. The Company has also experienced additional net cash inflows into the various products and strategies during 2025 and has increased its customer accounts during the quarter.

    The Company’s operating income for the third quarter of $2.9 million was positively impacted by the increased revenues, which were only partially offset by a variety of higher operating expenses, including higher commissions and higher distribution costs. Advisor only operating income, a non-GAAP measure, was $5.5 million for the third quarter of 2025, an increase of $4.0 million from 2024.

    The third quarter of 2025 included $129.4 million of investment income, net from our consolidated investment products, primarily from unrealized gains related to the increase in fair value of a private placement investment that completed an initial public offering.

    The Company experienced unrealized losses on investments of $7.0 million for the three months ended September 30, 2025, which was primarily the impact of a 12% decline in the fair value of TPL during the quarter. In addition, the Company’s equity losses, net, were $2.0 million from various equity interest holdings. These unrealized losses were partially offset by the unrealized gains of $1.3 million for the three months ended September 30, 2025 from its digital asset holdings.

    On November 11, 2025, the Company’s Board of Directors declared a cash dividend of $0.106 per share, payable on December 17, 2025, to shareholders of record as of the close of business on November 25, 2025.

    Conference Call

    Murray Stahl, Chairman and Chief Executive Officer, and Mark Herndon, Chief Financial Officer, will host a conference call on Tuesday, November 18, 2025 at 4:15 pm EST. You may register for the conference call by clicking on the following link:
    https://register.gotowebinar.com/register/3809689494263827541
    Phone Access: +1 (562) 247-8422 Access Code: 840-658-383
    Only online participants can submit questions during the webinar.

    HORIZON KINETICS HOLDING CORPORATION
    Consolidated Statements of Operations
    (in thousands)

    Three Months Ended September 30,

    Nine Months Ended September 30,

    2025

    2024

    2025

    2024
    Revenue:
    Management and advisory fees

    $

    17,764

    $

    13,036

    $

    55,465

    $

    37,277
    Other income and fees

    129

    23

    345

    288
    Total revenue

    17,893

    13,059

    55,810

    37,565
    Operating expenses:
    Compensation and related employee benefits

    7,685

    7,220

    24,718

    19,903
    Sales, distribution and marketing

    3,774

    2,972

    12,048

    7,881
    Depreciation and amortization

    199

    455

    917

    1,374
    General and administrative expenses

    2,520

    2,744

    7,728

    7,397
    Expenses of consolidated investment products

    766

    590

    2,078

    1,651
    Total operating expenses

    14,944

    13,981

    47,489

    38,206
    Operating income (loss)

    2,949

    (922

    )

    8,321

    (641

    )
    Other income (expense):
    Equity earnings (losses), net

    (2,033

    )

    1,617

    (3,543

    )

    3,683
    Interest and dividends

    530

    891

    1,475

    1,261
    Other income (expense)

    (290

    )

    (2,676

    )

    (530

    )

    (2,857

    )
    Investment and other income (losses) of consolidated investment products, net

    129,399

    142,620

    184,133

    442,469
    Interest and dividend income of consolidated investment products

    1,627

    8,888

    6,418

    17,494
    Unrealized gain (loss) on digital assets, net

    1,260

    (95

    )

    2,908

    2,792
    Realized gain (loss) on investments, net

    32

    23

    2,229

    342
    Unrealized gain (loss) on investments net

    (7,046

    )

    11,321

    (8,734

    )

    24,942
    Total other income, net

    123,479

    162,589

    184,356

    490,126
    Income (loss) from continuing operations before provision for income taxes

    126,428

    161,667

    192,677

    489,485
    Income tax (expense) benefit

    10,370

    (69,296

    )

    3,840

    (70,774

    )
    Income (loss) from continuing operations, net of tax

    136,798

    92,371

    196,517

    418,711
    Income (loss) from discontinued operations, net of tax

    (63

    )

    (147

    )

    (1,300

    )

    (147

    )
    Net income

    $

    136,735

    $

    92,224

    $

    195,217

    $

    418,564
    Less: net income attributable to redeemable noncontrolling interests

    (129,500

    )

    (130,391

    )

    (175,630

    )

    (401,852

    )
    Net (loss) income attributable to Horizon Kinetics Holding Corporation

    $

    7,235

    $

    (38,167

    )

    $

    19,587

    $

    16,712
    Basic and diluted net (loss) income per common share:
    Net income (loss) from continuing operations

    $

    7.34

    $

    5.02

    $

    10.55

    $

    23.10
    Net income (loss) from discontinued operations

    $

    (0.00

    )

    $

    (0.01

    )

    $

    (0.07

    )

    $

    (0.01

    )
    Net income (loss) attributable to Horizon Kinetics Holding Corporation

    $

    0.39

    $

    (2.07

    )

    $

    1.05

    $

    0.92
    Weighted average shares outstanding:
    Basic and diluted

    18,635

    18,415

    18,635

    18,129

    HORIZON KINETICS HOLDING CORPORATION
    Consolidated Statements of Financial Condition
    (in thousands)

    September 30,

    December 31,

    2025

    2024

    (Unaudited)
    Assets
    Cash and cash equivalents

    $

    37,723

    $

    14,446
    Fees receivable, net

    6,816

    8,344
    Investments, at fair value

    83,060

    91,435
    Assets of consolidated investment products
    Cash and cash equivalents

    24,334

    44,306
    Investments, at fair value

    1,891,832

    1,746,850
    Other assets

    23,941

    19,247
    Other investments

    21,776

    13,443
    Operating lease right-of-use assets

    6,952

    5,105
    Property and equipment, net

    95

    99
    Prepaid expenses and other assets

    5,295

    1,728
    Due from affiliates

    28

    27
    Digital assets

    16,198

    13,240
    Assets of discontinued operations

    –

    4,364
    Intangible assets, net

    41,292

    42,169
    Goodwill

    23,373

    23,373
    Total assets

    $

    2,182,715

    $

    2,028,176
    Liabilities, Noncontrolling Interests, and Shareholders’ Equity
    Liabilities:
    Accounts payable, accrued expenses and other

    $

    16,420

    $

    21,547
    Accrued third party distribution expenses

    417

    6,522
    Deferred revenue

    60

    222
    Liabilities of consolidated investment products
    Accounts payable and accrued expenses

    3,864

    1,486
    Other liabilities

    426

    2,793
    Deferred tax liability, net

    80,933

    95,683
    Due to affiliates

    7,750

    11,597
    Liabilities of discontinued operations

    –

    464
    Operating lease liability

    8,868

    7,379
    Total liabilities

    118,738

    147,693
    Commitments and contingencies
    Redeemable noncontrolling interests

    1,708,580

    1,540,312
    Shareholders’ equity
    Preferred stock, no par value, authorized 20,000 shares; no shares issued and outstanding

    –

    –
    Common stock; $0.10 par value, authorized 50,000 shares; issued and outstanding 18,635 shares, net of treasury stock; 1 share at September 30, 2025 and December 31, 2024, respectively

    1,864

    1,864
    Additional paid-in capital

    39,243

    39,243
    Retained earnings

    314,290

    299,064
    Total shareholders’ equity

    355,397

    340,171
    Total liabilities, noncontrolling interests, and shareholders’ equity

    $

    2,182,715

    $

    2,028,176

    Additional Information about our performance

    The Company consolidates certain private funds in order for the consolidated financial statements to conform with generally accepted accounting principles. As a result, the assets and liabilities of the applicable consolidated funds are presented on the Company’s consolidated statements of financial condition. Additionally, an amount that represents the Company’s clients’ interests in these consolidated private funds will be presented as redeemable noncontrolling interests on the Company’s consolidated statements of financial condition. The investment income (losses), other income (losses) and the expenses of the consolidated investment products will be presented within the Company’s consolidated statements of operations. Additionally, an amount that represents the net income attributable to redeemable noncontrolling interests as well as the net income (loss) attributable to Horizon Kinetics Holding Corporation will be presented on the Company’s consolidated statement of operations.

    Consolidated Investment Products (“CIPs”) consist of certain private investment funds which are sponsored by the Company. The Company has no right to the CIPs’ assets, other than its direct equity investments in them and investment management and other fees earned from them. The liabilities of the CIPs have no recourse to the Company’s assets beyond the level of its direct investment, therefore the Company bears no other risks associated with the CIPs’ liabilities.

    As indicated in the additional information presented in the tables below, there are several notable presentational differences as a result of the consolidation of the CIPs:

    • Management and advisory fees from CIPs, including incentive fees, are eliminated from consolidated revenues. Accordingly, our presentation without the CIPs reflects an increased revenue growth to $19.6 million, a 31% increase from the third quarter of 2024.

    • The presentation of Operating income without the CIPs includes the revenues to the advisor only and excludes the line item expenses of consolidated investment products. Management views this operating measure as a useful tool because it is prior to the impact of various fair value measurements of investments and digital assets, which can be volatile from quarter to quarter.

    • The equity in earnings of private funds, which results primarily from CIPs, is eliminated from the consolidated presentation as that activity is included within the investment results of the CIPs. Accordingly, our presentation without the CIPs reflects an increased level of equity earnings that presents an increase in the value of our holdings within the CIPs.

    • Stockholders’ equity and net income attributable to Horizon Kinetics Holding Corporation are not impacted by the consolidation process.

    • The Statement of Financial Condition without the consolidation of private funds presents lower total assets as a result of excluding the total assets held by the CIPs as well as the associated redeemable noncontrolling interests, which represents our clients’ interests in these funds. A portion of the total assets held by private funds continues to relate to $247.5 million of economic interests held by Horizon Kinetics Holding Corporation, which is reflected in Other Investments in the presentation below.

    HORIZON KINETICS HOLDING CORPORATION
    Statements of Operations (Unaudited)
    (in thousands)

    (Advisor only: without consolidation of private funds)

    Three Months Ended September 30,

    Nine Months Ended September 30,

    2025

    2024

    2025

    2024
    Revenue:
    Management and advisory fees

    $

    19,561

    $

    14,933

    $

    61,240

    $

    41,735
    Other income and fees

    129

    23

    345

    288
    Total revenue

    19,690

    14,956

    61,585

    42,023
    Operating expenses:
    Compensation, related employee benefits

    7,685

    7,220

    24,718

    19,903
    Sales, distribution and marketing

    3,774

    2,972

    12,048

    7,881
    Depreciation and amortization

    199

    455

    917

    1,374
    General and administrative expenses

    2,540

    2,773

    7,792

    7,464
    Expenses of consolidated investment products

    –

    –

    –

    –
    Total operating expenses

    14,198

    13,420

    45,475

    36,622
    Operating income (loss)

    5,492

    1,536

    16,110

    5,401
    Other income (expense):
    Equity in earnings of proprietary funds, net

    (3,050

    )

    20,276

    3,589

    55,752
    Interest and dividends

    530

    891

    1,475

    1,261
    Other income (expense)

    (290

    )

    (2,676

    )

    (530

    )

    (2,857

    )
    Investment and other income (losses) of consolidated investment products, net

    –

    –

    –

    –
    Interest and dividend income of consolidated investment products

    –

    –

    –

    –
    Unrealized (loss) gain on digital assets, net

    1,260

    (95

    )

    2,908

    2,792
    Realized gain on investments, net

    32

    23

    2,229

    342
    Unrealized gain (loss) on investments net

    (7,046

    )

    11,321

    (8,734

    )

    24,942
    Total other income (expense), net

    (8,564

    )

    29,740

    937

    82,232
    Income (loss) from continuing operations before provision for income taxes

    (3,072

    )

    31,276

    17,047

    87,633
    Income tax (expense) benefit

    10,370

    (69,296

    )

    3,840

    (70,774

    )
    Income (loss) from continuing operations, net of tax

    7,298

    (38,020

    )

    20,887

    16,859
    Income (loss) from discontinued operations, net of tax

    (63

    )

    (147

    )

    (1,300

    )

    (147

    )
    Net income (loss)

    $

    7,235

    $

    (38,167

    )

    $

    19,587

    $

    16,712
    Less: net income attributable to redeemable noncontrolling interests

    –

    –

    –

    –
    Net income (loss) attributable to Horizon Kinetics Holding Corporation

    $

    7,235

    $

    (38,167

    )

    $

    19,587

    $

    16,712
    Basic and diluted net income (loss) per common share:
    Net income (loss)

    $

    0.39

    $

    (2.07

    )

    $

    1.05

    $

    0.92
    Weighted average shares outstanding:
    Basic and diluted

    18,635

    18,415

    18,635

    18,129

    Nine Months Ended September 30, 2025

    Consolidated Company Entities

    Consolidated Investment Products

    Eliminations

    Consolidated
    Revenue:
    Management and advisory fees

    $

    61,240

    $

    –

    $

    (5,775

    )

    $

    55,465
    Other income and fees

    345

    –

    345
    Total revenue

    61,585

    –

    (5,775

    )

    55,810
    Operating expenses:
    Compensation, related employee benefits, and cost of goods sold

    24,718

    –

    –

    24,718
    Sales, distribution and marketing

    12,048

    –

    –

    12,048
    Depreciation and amortization

    917

    –

    –

    917
    General and administrative expenses

    7,792

    –

    (64

    )

    7,728
    Expenses of consolidated investment products

    –

    2,014

    64

    2,078
    Total operating expenses

    45,475

    2,014

    –

    47,489
    Operating income (loss)

    16,110

    (2,014

    )

    (5,775

    )

    8,321
    Other income (expense):
    Equity in earnings of proprietary funds, net

    3,589

    –

    (7,132

    )

    (3,543

    )
    Interest and dividends

    1,475

    –

    –

    1,475
    Other income (expense)

    (530

    )

    –

    –

    (530

    )
    Investment and other income (losses) of consolidated investment products, net

    –

    184,133

    –

    184,133
    Interest and dividend income of consolidated investment products

    –

    6,418

    –

    6,418
    Management fees of consolidated investment products

    –

    (5,498

    )

    5,498

    –
    Unrealized (loss) gain on digital assets, net

    2,908

    –

    –

    2,908
    Realized gain on investments, net

    2,229

    –

    –

    2,229
    Unrealized gain (loss) on investments net

    (8,734

    )

    –

    –

    (8,734

    )
    Total other income (expense), net

    937

    185,053

    (1,634

    )

    184,356
    Income (loss) from continuing operations before provision for income taxes

    17,047

    183,039

    (7,409

    )

    192,677
    Income tax (expense) benefit

    3,840

    –

    –

    3,840
    Net income (loss) from continuing operations, net of tax

    20,887

    183,039

    (7,409

    )

    196,517
    Net Income (loss) from discontinued operations, net of tax

    (1,300

    )

    –

    –

    (1,300

    )
    Net income (loss)

    $

    19,587

    $

    183,039

    $

    (7,409

    )

    $

    195,217
    Less: net income (loss) attributable to redeemable noncontrolling interests

    –

    (149,487

    )

    (26,143

    )

    (175,630

    )
    Net income (loss) attributable to Horizon Kinetics Holding Corporation

    $

    19,587

    $

    33,552

    $

    (33,552

    )

    $

    19,587

    HORIZON KINETICS HOLDING CORPORATION
    Statements of Financial Condition (Unaudited)
    (in thousands)

    (Advisor only: without consolidation of private funds)

    September 30,

    December 31,

    2025

    2024
    Assets
    Cash and cash equivalents

    $

    37,723

    $

    14,446
    Fees receivable

    8,345

    58,720
    Investments, at fair value

    83,060

    91,435
    Assets of consolidated investment products
    Cash and cash equivalents

    –

    –
    Investments, at fair value

    –

    –
    Other assets

    –

    –
    Other Investments

    247,484

    228,870
    Operating lease right-of-use assets

    6,952

    5,105
    Property and equipment, net

    95

    99
    Prepaid expenses and other assets

    5,295

    1,729
    Due from affiliates

    28

    34
    Digital assets

    16,198

    13,240
    Assets of discontinued operations

    –

    4,345
    Intangible assets, net

    41,292

    42,169
    Goodwill

    23,373

    23,393
    Total Assets

    $

    469,845

    $

    483,585
    Liabilities, Noncontrolling Interests, and Shareholders Equity
    Liabilities:
    Accounts payable, accrued expenses and other

    $

    16,420

    $

    21,547
    Accrued third party distribution expenses

    417

    6,522
    Deferred revenue

    60

    222
    Liabilities of consolidated investment products
    Accounts payable and accrued expenses

    –

    –
    Other liabilities

    –

    –
    Deferred tax liability, net

    80,933

    95,683
    Due to affiliates

    7,750

    11,597
    Liabilities of discontinued operations

    –

    464
    Operating lease liability

    8,868

    7,379
    Total Liabilities

    114,448

    143,414
    Commitments and contingencies
    Redeemable Noncontrolling Interests

    –

    –
    Shareholders’ Equity
    Preferred stock, no par value, authorized 20,000 shares; no shares issued and outstanding

    –

    –
    Common stock; $0.10 par value, authorized 50,000 shares; issued and outstanding 18,635 shares, net of treasury stock; 1 share at September 30, 2025 and December 31, 2024, respectively

    1,864

    1,864
    Additional paid-in capital

    39,243

    39,243
    Retained earnings

    314,290

    299,064
    Total Shareholders’ Equity

    355,397

    340,171
    Total Liabilities, Noncontrolling Interests, and Shareholders’ Equity

    $

    469,845

    $

    483,585

    September 30, 2025

    Consolidated Company Entities

    Consolidated Investment Products

    Eliminations

    Consolidated
    Assets
    Cash and cash equivalents

    $

    37,723

    $

    –

    $

    –

    $

    37,723
    Fees receivable

    8,345

    –

    (1,529

    )

    6,816
    Investments, at fair value

    83,060

    –

    –

    83,060
    Assets of consolidated investment products
    Cash and cash equivalents

    –

    24,334

    –

    24,334
    Investments, at fair value

    –

    1,891,832

    –

    1,891,832
    Other assets

    –

    23,941

    –

    23,941
    Other investments

    247,484

    –

    (225,708

    )

    21,776
    Digital assets

    16,198

    –

    –

    16,198
    Intangible assets, net

    41,292

    –

    –

    41,292
    Goodwill

    23,373

    –

    –

    23,373
    Other assets

    12,370

    –

    –

    12,370
    Total assets

    $

    469,845

    $

    1,940,107

    $

    (227,237

    )

    $

    2,182,715
    Liabilities, Noncontrolling Interests, and Shareholders’ Equity
    Liabilities:
    Accounts payable, accrued expenses and other

    $

    16,420

    $

    –

    $

    –

    $

    16,420
    Accrued third party distribution expenses

    417

    –

    –

    417
    Deferred revenue

    60

    –

    –

    60
    Liabilities of consolidated investment products
    Accounts payable and accrued expenses

    –

    3,864

    –

    3,864
    Due to affiliates

    –

    1,575

    (1,575

    )

    –
    Other liabilities

    –

    426

    –

    426
    Deferred tax liability, net

    80,933

    –

    –

    80,933
    Due to affiliates

    7,750

    –

    –

    7,750
    Operating lease liability

    8,868

    –

    –

    8,868
    Total liabilities

    114,448

    5,865

    (1,575

    )

    118,738
    Commitments and contingencies
    Redeemable noncontrolling interests

    –

    1,750,408

    (41,828

    )

    1,708,580
    Equity interests

    355,397

    183,834

    (183,834

    )

    355,397
    Total liabilities, noncontrolling interests, and shareholders’ equity

    $

    469,845

    $

    1,940,107

    $

    (227,237

    )

    $

    2,182,715

    Non-GAAP Measures

    In discussing financial results, the Company presented tables without the consolidation of certain private funds (also labeled “Advisor only”) which is not in accordance with Generally Accepted Accounting Principles (GAAP). We use this non-GAAP financial measure internally to make operating and strategic decisions, including evaluating our overall performance and as a factor in determining compensation for certain employees. We believe presenting this non-GAAP financial measure provides additional information to facilitate comparison of our historical operating costs and their trends, and provides additional transparency on how we evaluate our financial condition and results of operations. We also believe presenting this measure allows investors to view our financial condition and results of operations using the same measure that we use in evaluating our performance and trends.

    Note Regarding Forward-Looking Statements

    This news release may contain “forward-looking statements” within the meaning of the federal securities laws that are intended to qualify for the Safe Harbor from liability established by the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” generally can be identified by the use of forward-looking terminology such as “assumptions,” “target,” “guidance,” “strategy,” “outlook,” “plans,” “projection,” “may,” “will,” “would,” “expect,” “intend,” “estimate,” “anticipate,” “believe”, “potential,” or “continue” (or the negative or other derivatives of each of these terms) or similar terminology.

    Forward-looking statements convey our expectations, intentions, or forecasts about future events, circumstances, or results. All forward-looking statements, by their nature, are subject to assumptions, risks, and uncertainties, which may change over time and many of which are beyond our control. You should not rely on any forward-looking statement as a prediction or guarantee about the future. Actual future objectives, strategies, plans, prospects, performance, conditions, or results may differ materially from those set forth in any forward-looking statement. Some of the factors that may cause actual results or other future events or circumstances to differ from those in forward-looking statements are described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 and the Company’s subsequent Quarterly Reports on Form 10-Q and other periodic reports filed with the Securities and Exchange Commission. Any forward-looking statement made by us or on our behalf speaks only as of the date that it was made. We do not undertake to update any forward-looking statement to reflect the impact of events, circumstances, or results that arise after the date that the statement was made, except as required by applicable securities laws. You, however, should consult further disclosures (including disclosures of a forward-looking nature) that we may make in any subsequent filings with the Securities and Exchange Commission.

    About Horizon Kinetics Holding Corporation

    Horizon Kinetics Holding Corporation (OTCID: HKHC) primarily offers investment advisory services through its subsidiary Horizon Kinetics Asset Management LLC (“HKAM”), a registered investment adviser. HKAM provides independent proprietary research and investment advisory services for mainly long-only and alternative value-based investing strategies. The firm’s offices are located in New York City, White Plains, New York, and Summit, New Jersey. For more information, please visit http://www.hkholdingco.com.

    Investor Relations Contact:

    ir@hkholdingco.com

    SOURCE: Horizon Kinetics Holding Corporation

    View the original press release on ACCESS Newswire

  • Survivors of Abuse NJ Highlights Efforts to Address Sexual Abuse Cases Across New Jersey

    Survivors of Abuse NJ Highlights Efforts to Address Sexual Abuse Cases Across New Jersey

    MT. LAUREL, NJ – November 14, 2025 – PRESSADVANTAGE –

    Survivors of Abuse NJ announced new initiatives focused on addressing the legal and institutional issues surrounding sexual abuse cases in Trenton, NJ. The organization, based in Trenton, continues its mission to improve public understanding of survivors’ rights and to strengthen accountability within organizations where abuse has occurred. The effort reflects a broader commitment to ensuring that survivors have access to accurate information about the civil justice process and recent legislative reforms.

    “Civil actions involving sexual abuse require a careful approach that combines legal precision with sensitivity to trauma,” said Joseph L. Messa, Esq., attorney at Survivors of Abuse NJ. “Our focus is on ensuring survivors understand their options under New Jersey law and how the legal system can be used to pursue accountability for wrongdoing.”

    Trenton sexual abuse lawyer

    Sexual abuse cases in the civil system often involve complex layers of responsibility, encompassing both individual perpetrators and the institutions that enabled or failed to prevent the misconduct. Claims can arise from schools, medical facilities, religious organizations, and other entities that have a duty to protect those in their care. Courts in New Jersey regularly review whether institutions maintained appropriate oversight, followed reporting procedures, and took reasonable steps to prevent abuse. The outcomes of these cases frequently prompt reforms designed to improve monitoring, transparency, and compliance with state-mandated standards.

    Recent developments in New Jersey’s legislative framework have expanded the rights of survivors seeking civil redress. The New Jersey Child Victims Act, enacted in 2019, extended the statute of limitations for filing claims of childhood sexual abuse. Under this law, survivors may bring civil claims until age fifty-five or within seven years of recognizing the harm caused by the abuse. The act also opened a temporary two-year window for previously time-barred claims, enabling many individuals to pursue justice for the first time. These reforms demonstrate a statewide commitment to addressing historical barriers that have long prevented survivors from seeking accountability.

    Litigation involving sexual abuse in New Jersey often requires coordination among legal professionals, investigators, and mental health experts. Evidence in such cases may include institutional records, correspondence, and prior complaint documentation, all of which help determine whether organizations fulfilled their duty of care. Courts examine whether administrators or supervisors responded appropriately to warning signs and whether systems were in place to detect and report misconduct. The goal of these proceedings extends beyond compensation to include meaningful institutional reform that promotes safer environments.

    Survivors of Abuse NJ provides educational materials and legal resources explaining how civil claims are initiated and what remedies may be available. The organization’s attorneys work to clarify procedural requirements, from the filing of complaints to evidentiary standards used in court. Through outreach initiatives, the firm aims to increase awareness about the rights of survivors and to reduce confusion surrounding the complexities of sexual abuse litigation. These resources are designed to empower survivors with factual, objective information that supports informed decision-making.

    The organization’s approach to representation is rooted in trauma-informed practices. Attorneys within Survivors of Abuse NJ collaborate with mental health professionals to ensure that survivors’ experiences are handled with care and respect. Clear communication and client autonomy remain central to the firm’s model, ensuring that individuals remain in control of their decisions throughout the process. The organization’s attorneys have experience managing civil cases that involve institutional misconduct, professional negligence, and related forms of abuse, reflecting an understanding of the sensitive issues involved in these matters.

    Survivors of Abuse NJ also participates in public education efforts designed to inform communities about existing protections under state law. These efforts include seminars, informational materials, and partnerships with advocacy organizations that promote accountability and transparency. By engaging with community organizations, the firm contributes to the broader dialogue about how legal and institutional systems can better support survivors and prevent future harm.

    Attorney Joseph L. Messa, Esq., has been involved in numerous civil actions concerning misconduct within institutional and professional settings. His recognition in this field highlights the growing importance of survivor-centered advocacy within the legal system. As awareness increases, survivors and legal professionals continue to collaborate in identifying ways to strengthen enforcement, improve reporting mechanisms, and ensure fair access to justice.

    Survivors of Abuse NJ remains dedicated to advancing knowledge, legal transparency, and ethical accountability in the handling of sexual abuse cases. The organization continues to monitor changes in state legislation and case law, sharing updates through its public resources and community partnerships. Through education, outreach, and litigation, it aims to promote systems that protect survivors and prevent misconduct across institutional settings.

    For more information, visit the Survivors of Abuse NJ website.

    ###

    For more information about Joseph L. Messa, Esq. – The Abuse Lawyer NJ, contact the company here:

    Joseph L. Messa, Esq. – The Abuse Lawyer NJ
    Joseph L. Messa, Esq.
    (848) 290-7929
    joe@survivorsofabusenj.com
    2000 Academy Dr., Suite 200
    Mt. Laurel, NJ 08054

  • Survivors of Abuse NJ Expands Resources for Sexual Abuse Survivors

    Survivors of Abuse NJ Expands Resources for Sexual Abuse Survivors

    MT. LAUREL, NJ – November 13, 2025 – PRESSADVANTAGE –

    Survivors of Abuse NJ announced the expansion of its informational and educational resources designed to support sexual abuse survivors across New Jersey. Based in Cherry Hill, the organization provides civil legal representation and trauma-informed guidance to individuals impacted by sexual abuse in institutional, professional, or private settings. The initiative reflects the firm’s commitment to increasing awareness of survivors’ rights under New Jersey law and to strengthening access to accurate information about the civil justice process.

    “Reliable information is essential for survivors as they consider their options and take steps toward accountability,” said Joseph L. Messa, Esq., attorney at Survivors of Abuse NJ. “Our goal is to provide clear, factual resources that help individuals understand their rights under the law and the processes available to pursue justice.”

    sexual abuse lawyer Cherry Hill, NJ

    The organization’s expanded resources include legal education materials, outreach programs, and informational content outlining the procedures for filing civil claims related to sexual abuse. These materials address common questions about statutes of limitation, institutional liability, and the difference between civil and criminal actions. Survivors of Abuse NJ created these resources to bridge the knowledge gap that often prevents survivors from accessing justice and to ensure that they are fully informed about their legal rights under state law.

    Civil claims for sexual abuse in Cherry Hill, NJ may involve individuals, institutions, or both, depending on the circumstances of the case. Schools, medical facilities, religious organizations, and youth programs are among the entities that may bear responsibility for failing to prevent or respond to abuse. Civil litigation in these cases examines whether organizations implemented appropriate oversight, complied with mandatory reporting requirements, and took reasonable steps to protect those under their care. Survivors of Abuse NJ assists clients in evaluating these factors and determining which legal avenues may apply.

    Legislative reforms in New Jersey have significantly expanded the rights of sexual abuse survivors to seek justice. The New Jersey Child Victims Act (CVA), enacted in 2019, extended the statute of limitations for childhood sexual abuse claims and opened a two-year window allowing survivors of previously time-barred cases to file lawsuits. The law now permits survivors to file civil actions until age fifty-five or within seven years of recognizing the harm caused by the abuse. Survivors of Abuse NJ continues to educate survivors about these provisions, helping them understand the legal implications and deadlines involved in pursuing a civil claim.

    The organization’s trauma-informed approach to legal representation prioritizes survivor autonomy, confidentiality, and respect throughout the process. Attorneys collaborate with mental health professionals, investigators, and advocacy organizations to ensure survivors are supported at every stage of their case. This multidisciplinary approach balances legal precision with compassion, acknowledging the emotional and psychological effects that survivors experience while navigating the legal system.

    Survivors of Abuse NJ also engages in public education and community partnerships to promote awareness of survivor rights and available legal resources. The firm’s outreach efforts include seminars, written guides, and community collaborations designed to educate the public about recognizing abuse, understanding reporting obligations, and accessing justice. These initiatives aim to reduce stigma, encourage transparency, and promote institutional accountability throughout New Jersey.

    Civil litigation for sexual abuse cases not only provides compensation for survivors but also promotes systemic change. Legal actions often lead to reforms in policies, reporting protocols, and training within organizations found to have failed in their duties of care. By pursuing these cases, survivors contribute to broader societal efforts to strengthen prevention measures and improve institutional accountability. Survivors of Abuse NJ’s work in this area reinforces the importance of both individual justice and collective reform.

    Attorney Joseph L. Messa, Esq., brings decades of experience in complex civil litigation, including cases involving institutional misconduct and professional negligence. His leadership has guided the firm’s expansion of survivor-focused initiatives that combine education, advocacy, and legal representation. Under his direction, Survivors of Abuse NJ continues to serve as a resource for individuals seeking to understand their legal rights and to promote reforms that protect future generations.

    Survivors of Abuse NJ remains dedicated to advancing awareness, accountability, and access to justice for sexual abuse survivors across the state. Through its expanded resources, educational programs, and civil advocacy, the organization continues to strengthen the systems designed to protect survivors and uphold their rights under New Jersey law.

    For more information, visit the Survivors of Abuse NJ website. To learn more about educational and legal resources for sexual abuse survivors, contact Survivors of Abuse NJ directly.

    ###

    For more information about Joseph L. Messa, Esq. – The Abuse Lawyer NJ, contact the company here:

    Joseph L. Messa, Esq. – The Abuse Lawyer NJ
    Joseph L. Messa, Esq.
    (848) 290-7929
    joe@survivorsofabusenj.com
    2000 Academy Dr., Suite 200
    Mt. Laurel, NJ 08054

  • Medicus Pharma Ltd. Receives Full United Kingdom Regulatory and Ethical Approvals To Expand Phase 2 Clinical Study (SKNJCT-003) To Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

    Medicus Pharma Ltd. Receives Full United Kingdom Regulatory and Ethical Approvals To Expand Phase 2 Clinical Study (SKNJCT-003) To Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

    THE SKNJCT-003 CLINICAL STUDY EXPANSION INTO THE UNITED KINGDOM TO FURTHER ENABLE GLOBAL PATIENT RECRUITMENT AND CLINICAL DATASET TOWARD A PIVOTAL STUDY PROGRAM

    PHILADELPHIA, PA / ACCESS Newswire / November 13, 2025 / Medicus Pharma Ltd. (NASDAQ:MDCX) (“Medicus” or the “Company”), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, is pleased to announce that it has received full regulatory and ethical approvals in the United Kingdom to expand its ongoing Phase 2 clinical study (SKNJCT-003) evaluating Doxorubicin Microneedle Array (D-MNA) to non-invasively treat basal cell carcinoma (BCC) of the skin.

    The phase 2 clinical study (SKNJCT-003) which is currently underway in nine (9) clinical sites in United States can now expand into additional sites in United Kingdom.

    The approvals were issued by the Medicines and Healthcare products Regulatory Agency (MHRA), the Health Research Authority (HRA) and the Wales Research Ethics Committee (WREC). The MHRA approval followed a comprehensive scientific review of the Investigational Medicinal Product Dossier (IMPD) and protocol. The WREC issued a favorable ethical opinion, and the HRA granted study wide governance approval, confirming compliance with U.K. Good Clinical Practice and National Health Service (NHS) capacity and capability standards.

    “The United Kingdom regulatory and ethical approval is another major step forward in establishing a global footprint of our novel, non-invasive treatment for BCC of the skin, which we believe represents more than $2 billion in potential market opportunity,” stated Dr. Raza Bokhari, Medicus’s Executive Chairman & CEO. “With clinical development programs now active across United States, Europe, and the Middle East, we are enhancing global patient recruitment and clinical dataset which, among other things, would assist us in designing a robust pivotal program”.

    SKNJCT-003 Clinical Trial Design
    The SKNJCT-003 clinical study is designed to be a randomized, double-blind, placebo-controlled (P-MNA), multi-center study enrolling up to 90 subjects presenting with BCC of the skin. The study evaluates the efficacy of two dose levels of D-MNA compared to a placebo control. The participants will be randomized 1:1:1 to one of three groups: a placebo-controlled group receiving P-MNA, a low-dose group receiving 100μg of D-MNA, and a high-dose group receiving 200μg of D-MNA.

    The high-dose, 200μg D-MNA, in the study is the maximum dose that was used in the Company’s Phase 1 safety and tolerability study (SKNJCT-001) completed in March 2021.

    SKNJCT-001 met its primary objective of safety and tolerability. The investigational product, D-MNA, was well tolerated across all dose levels in all 13 participants enrolled in the study, with no dose-limiting toxicities (DLTs), or serious adverse events (SAEs). Furthermore, there were no systemic effects or clinically significant abnormal findings in laboratory parameters, vital signs, ECGs, and physical examinations. The study also describes the efficacy of the investigational product, D-MNA, with 6 participants experiencing complete responses. The complete response is defined as the disappearance of BCC histologically in the final excision at the end of study visit. The participants profile demonstrating complete responses was diverse, and all participants (6/6) had nodular subtype of BCC.

    In March 2025, the Company announced a positively trending interim analysis for SKNJCT-003 demonstrating more than 60% clinical clearance. The interim analysis was conducted after more than 50% of the then-targeted 60 patients in the study were randomized. The findings of the interim analysis are preliminary and may or may not correlate with the findings of the study once completed. In April 2025, the investigational review board approved to increase the number of participants in SKNJCT-003 to ninety (90) subjects. The Company is expanding its trial sites in Europe and has randomized more than 75% of the ninety (90) participants expected to be randomized in the study. In September 2025, the Company received positive feedback from the Food and Drug Administration (FDA) regarding its Type C meeting supporting the development of Skinject, indicating that the Company may follow 505(b)(2) regulatory pathway to non-invasively treat BCC using dissolvable D-MNA.

    The Company also has a clinical study (SKNJCT-004) currently underway in the United Arab Emirates (UAE). The study is expected to randomize thirty-six (36) patients in six (6) sites in the UAE. Cleveland Clinic Abu Dhabi (CCAD) is the principal investigator, along with Sheikh Shakbout Medical City (SSMC), Burjeel Medical City (BMC), Rashid Hospital (RH), Clemenceau Medical Center (CMC) and American Hospital of Dubai (AHD). Insights Research Organization and Solutions (IROS), a UAE-based contract research organization, is coordinating the clinical study for the Company. IROS is a M42 portfolio company.

    In August 2025, the Company completed the acquisition of Antev, a UK-based late clinical stage biotech company, developing Teverelix, a next generation GnRH antagonist, as a first in market product for cardiovascular high-risk advanced prostate cancer patients and patients with first acute urinary retention relapse (AURr) episodes due to enlarged prostate.

    Antev’s flagship drug candidate is Teverelix trifluoroacetate (Teverelix TFA), a long-acting gonadotrophin-releasing hormone (GnRH) antagonist. Unlike GnRH agonists, which can cause an initial surge in testosterone levels, Teverelix directly suppresses sex hormone production without this surge, potentially reducing cardiovascular risks. This mechanism is particularly beneficial for patients with existing cardiovascular conditions. Teverelix is formulated as a microcrystalline suspension, allowing for sustained release and a six-week dosing interval, which may improve patient compliance and outcomes.

    In October 2025, the company announced a strategic collaboration with the Gorlin Syndrome Alliance (GSA) to advance compassionate access to SKINJECT™, the Company’s investigational doxorubicin containing microneedle arrays (D-MNA) for patients suffering from Gorlin Syndrome, also known as nevoid basal cell carcinoma syndrome.

    Under the collaboration, Medicus and the GSA will jointly pursue the Expanded Access IND Program with the Food and Drug Administration (FDA) to allow patients with multiple, recurrent, or inoperable basal cell carcinomas (BCCs) to access SKINJECT™ under physician-supervised treatment protocols. The initiative aims to establish a framework for expanded access while collecting valuable real-world safety and tolerability data to inform future regulatory filings. It will also more tightly integrate patient community-led insights and data into the design, monitoring, and long-term development of SKINJECT™ in this rare disease population.

    For further information contact:
    Carolyn Bonner, President and Acting Chief Financial Officer
    (610) 636-0184
    cbonner@medicuspharma.com

    Anna Baran-Djokovic, SVP Investor Relations
    (305) 615-9162
    adjokovic@medicspharma.com

    About Medicus Pharma Ltd.
    Medicus Pharma Ltd. (NASDAQ:MDCX) is a biotech/life sciences company focused on accelerating the clinical development programs of novel and potentially disruptive therapeutics assets. The Company is actively engaged in multiple countries, spread over three continents.

    SkinJect Inc. a wholly owned subsidiary of Medicus Pharma Ltd., is a development stage, life sciences company focused on commercializing novel, non-invasive treatment for basal cell skin cancer using a patented dissolvable microneedle patch to deliver a chemotherapeutic agent to eradicate tumors cells. The Company completed a phase 1 safety & tolerability study (SKNJCT-001) in March of 2021, which met its primary objective of safety and tolerability; the study also describes the efficacy of the investigational product D-MNA, with six (6) participants experiencing complete response on histological examination of the resected lesion. The Company is currently conducting a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-003) in the United States and Europe. The Company has also commenced a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-004) in the United Arab Emirates.

    In August 2025, the Company announced its entry into a non-binding memorandum of understanding (the “MoU”) with Helix Nanotechnologies, Inc. (“HelixNano”), a Boston Based biotech company focused on developing a proprietary advanced mRNA platform, in respect of their shared mutual interest in the development or commercial arrangement contemplated by the MoU. The MoU is non-binding and shall not be construed to obligate either party to proceed with a joint venture or any further development or commercial arrangement, unless and until definitive agreements are executed.

    In August 2025, the Company completed the acquisition of Antev, a UK-based late clinical stage biotech company, developing Teverelix, a next generation GnRH antagonist, as a first in market product for cardiovascular high-risk advanced prostate cancer patients and patients with first acute urinary retention relapse (AURr) episodes due to enlarged prostate.

    Antev’s flagship drug candidate is Teverelix trifluoroacetate (Teverelix TFA), a long-acting gonadotrophin-releasing hormone (GnRH) antagonist. Unlike GnRH agonists, which can cause an initial surge in testosterone levels, Teverelix directly suppresses sex hormone production without this surge, potentially reducing cardiovascular risks. This mechanism is particularly beneficial for patients with existing cardiovascular conditions. Teverelix is formulated as a microcrystalline suspension, allowing for sustained release and a six-week dosing interval, which may improve patient compliance and outcomes.

    In September 2020, Antev completed a Phase 1 clinical trial in which Teverelix was shown to be well tolerated with no dose-limiting toxicities and demonstrated rapid testosterone suppression. The study included 48 healthy male volunteers. In February 2023, Antev also completed a Phase 2a study in fifty (50) patients with advanced prostate cancer (APC), where Teverelix achieved the primary endpoint of greater than 90% probability of castration levels of testosterone suppression (97.5%) but the secondary endpoint of maintaining this rate above 90% was not met with the probability dropping to 82.5% by Day 42.

    In January 2023, the FDA, reviewed the Phase 1 and Phase 2a data and provided written guidance on Antev’s proposed Phase 3 trial design for Teverelix. This milestone supports the Company’s clinical plans to develop Teverelix as a treatment for advanced prostate cancer patients with increased cardiovascular risk.

    In December 2023, FDA approved the Phase 2b study design in advanced prostate cancer covering 40 patients.

    In November 2024, FDA approved the Phase 2b study design in acute urinary retention covering 390 patients

    In October 2025, the company announced a strategic collaboration with the Gorlin Syndrome Alliance (GSA) to advance compassionate access to SKINJECT™, the Company’s investigational doxorubicin containing microneedle arrays (D-MNA) for patients suffering from Gorlin Syndrome, also known as nevoid basal cell carcinoma syndrome.

    Under the collaboration, Medicus and the GSA will jointly pursue the Expanded Access IND Program with the Food and Drug Administration (FDA) to allow patients with multiple, recurrent, or inoperable basal cell carcinomas (BCCs) to access SKINJECT™ under physician-supervised treatment protocols. The initiative aims to establish a framework for expanded access while collecting valuable real-world safety and tolerability data to inform future regulatory filings. It will also more tightly integrate patient community-led insights and data into the design, monitoring, and long-term development of SKINJECT™ in this rare disease population.

    Cautionary Notice on Forward-Looking Statements
    Certain information in this news release constitutes “forward-looking information” under applicable securities laws. “Forward-looking information” is defined as disclosure regarding possible events, conditions or financial performance that is based on assumptions about future economic conditions and courses of action and includes, without limitation, the collaboration with GSA including the potential benefits thereof for GSA, those suffering with Gorlin Syndrome and Medicus (including as it relates to the development of SkinJect), ability to be approved for the Expanded Access IND Program to enable those suffering with Gorlin Syndrome to access SKINJECT™ under physician-supervised treatment protocols, the development of Teverelix and expectations concerning, and future outcomes relating to, the development, advancement and commercialization of Teverelix for AURr and high CV risk prostate cancer, and the potential market opportunities related thereto, the MOU, including the potential signing of definitive agreements between Medicus and HelixNano and the development of thermostable infectious diseases vaccines by combining HelixNano’s proprietary mRNA vaccine platform with Medicus’s proprietary microneedle array (MNA) delivery platform, the Company’s aim to fast-track the clinical development program and convert the SKNJCT-003 exploratory clinical trial into a pivotal clinical trial, and approval from the FDA and the timing thereof, plans and expectations concerning, and future outcomes relating to, the development, advancement and commercialization of SkinJect through SKNJCT-003 and SKNJCT-004, and the potential market opportunities related thereto, the expansion of SKNJCT-003 into the United Kingdom and the potential benefits therefrom, the advancement of the SKNJCT-004 study and the potential results of and benefits of such study. Forward-looking statements are often but not always, identified by the use of such terms as “may”, “on track”, “aim”, “might”, “will”, “will likely result”, “could,” “designed,” “would”, “should”, “estimate”, “plan”, “project”, “forecast”, “intend”, “expect”, “anticipate”, “believe”, “seek”, “continue”, “target”, “potential” or the negative and/or inverse of such terms or other similar expressions. These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including those risk factors described in the Company’s annual report on form 10-K for the year ended December 31, 2024 (the “Annual Report”), and in the Company’s other public filings on EDGAR and SEDAR+, which may impact, among other things, the trading price and liquidity of the Company’s common shares. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect our expectations as of the date hereof and thus are subject to change thereafter. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.

    SOURCE: Medicus Pharma Ltd

    View the original press release on ACCESS Newswire

  • Tamra Bedford, Cosmetic RN Highlights Advanced Microneedling Expertise for Clients

    Tamra Bedford, Cosmetic RN Highlights Advanced Microneedling Expertise for Clients

    San Ramon, California – November 12, 2025 – PRESSADVANTAGE –

    Tamra Bedford, Cosmetic RN, a leading medical spa in San Ramon, emphasizes its specialized expertise in advanced microneedling treatments as demand for non-invasive skin rejuvenation continues to grow throughout the Bay Area. The medical spa, operated by registered nurse Tamra Bedford, focuses on delivering professional-grade collagen induction therapy to address various skin concerns, including fine lines, acne scarring, and uneven skin texture.

    The emphasis on microneedling comes as more clients seek effective alternatives to surgical procedures for skin rejuvenation. Microneedling, also known as collagen induction therapy, uses controlled micro-injuries to stimulate the body’s natural healing response, promoting increased collagen and elastin production. This process results in improved skin texture, reduced appearance of fine lines and wrinkles, and enhanced overall skin tone.

    Tamra Bedford, Cosmetic RN in San Ramon, California

    “Microneedling has become one of our most requested treatments because clients see real, lasting improvements in their skin quality,” said Tamra Bedford, registered nurse and owner of the medical spa. “The technology we use allows us to customize treatment depth and intensity based on each client’s specific skin concerns, whether they’re dealing with acne scarring, enlarged pores, or signs of aging.”

    The medical spa serves clients from throughout the Bay Area who seek professional-grade skincare treatments in a medical setting. As a Cosmetic RN with extensive training in aesthetic procedures, Bedford brings clinical expertise to each treatment, ensuring both safety and optimal results. The spa operates under the medical direction of Dr. Stephen Ronan, MD FACS, as part of Blackhawk Plastic Surgery.

    The growing interest in microneedling San Ramon reflects broader trends in aesthetic medicine toward minimally invasive procedures with minimal downtime. Clients typically experience mild redness immediately following treatment, similar to a mild sunburn, which subsides within 24 to 48 hours. Most clients require a series of treatments spaced four to six weeks apart for optimal results.

    Advanced microneedling treatments at the spa incorporate medical-grade equipment and sterile technique protocols typically found in medical facilities. The procedure can address multiple skin concerns simultaneously, making it an efficient option for clients looking to improve overall skin quality. Treatment areas commonly include the face, neck, décolletage, and hands.

    “What sets medical microneedling apart from at-home devices or non-medical treatments is the depth of penetration we can safely achieve and the sterile environment in which we operate,” added Bedford. “This allows us to deliver more dramatic results while maintaining the highest safety standards.”

    Beyond microneedling, the medical spa offers a comprehensive range of aesthetic services including laser hair removal, Botox and Dysport injections, dermal fillers, chemical peels, and IPL treatments for pigmentation concerns. This full spectrum of services allows the practice to create customized treatment plans that address multiple aesthetic goals.

    Tamra Bedford, Cosmetic RN operates as a physician-supervised medical spa specializing in non-surgical aesthetic treatments. The practice combines medical expertise with advanced technology to deliver safe, effective skincare solutions to clients throughout the San Ramon area and greater Bay Area region.

    ###

    For more information about Tamra Bedford, Cosmetic RN, contact the company here:

    Tamra Bedford, Cosmetic RN
    Tamra Bedford
    hello@tamrabedford.com
    2416 San Ramon Valley Blvd #200, San Ramon, CA 94583

  • Inspire Veterinary Partners Announces Third Quarter 2025 Financial Results

    Inspire Veterinary Partners Announces Third Quarter 2025 Financial Results

    Total revenues increase 7%; net losses decrease 27% compared to prior year period; comparable clinic revenues increase 9.2% vs prior year period

    VIRGINIA BEACH, VA / ACCESS Newswire / November 12, 2025 / Inspire Veterinary Partners, Inc. (Nasdaq:IVP) (“Inspire” or the “Company”), an owner and provider of pet health care services throughout the U.S., today reported financial results for the third quarter ended September 30, 2025.

    Third Quarter 2025 Financial Highlights Compared to Prior Periods

    • Total revenue of $4.3 million, a sequential increase of 1% from Q2 2025 and an increase of 7% from the prior year period.

    • Service revenue of $3.13 million, a sequential increase of 1% from Q2 2025 and an increase of 6% from the prior year period.

    • Product revenue of $1.17 million, a sequential increase of 8.2% from Q2 2025 and an increase of 9% from the prior year period.

    • Comparable clinic revenues increased 9.2% from the prior year period.

    • General and Administrative expenses decreased 19% from the prior year period.

    • Net loss of $2.5 million, a decrease of 27% from the prior year period.

    Third Quarter 2025 Operational Highlights

    • Announced launch of online pet pharmacy beginning Q1 2026.

    • Regained compliance with Nasdaq requirement for a minimum of $2.5 million in stockholders’ equity.

    • Presented corporate update at the H.C. Wainwright 27th Annual Global Investment Conference and met with institutional investors.

    Executive Commentary

    “The third quarter of 2025 was a solid quarter of continued progress for IVP and continues our trend of growth compared to the third quarter of 2024 as well as the second quarter of 2025,” said Kimball Carr, Inspire‘s Chairman, President and Chief Executive Officer. “Our team has brought innovative solutions to every aspect of our operations this year and we have celebrated significant clinical hiring that continues to propel our business forward. We continue to control costs and improve efficiency resulting in a 19% decrease in G&A expenses, and we narrowed net losses by 27% from $3.4 million to $2.5 million as compared to last year’s third quarter. After several successive quarters of improved earnings, we are incredibly focused on operations excellence as we continue to grow and move steadily toward profitability.

    “We are also extremely excited about new growth levers and look forward to the Q1 2026 launch of our online pet pharmacy. This planned new business vertical expands our offerings and differentiates our company in the evolving veterinary medicine industry,” concluded Mr. Carr.

    Third Quarter 2025 Financial Overview Compared to Prior Year Period

    • Total revenues for the third quarter of 2025 were $4.3 million, an increase of $267,107 or 7%, compared to $4.0 million for the third quarter of 2024.The year-over-year growth was primarily driven by improved appointment utilization and more consistent veterinarian staffing coverage across core hospitals.

    • Service revenues for the third quarter of 2025 were $3.13 million, an increase of $168,922 or 6%, compared to $2.96 million for the third quarter of 2024. Service revenue increased modestly, supported by higher appointment volume and stronger capture of wellness and preventive care services. The increase in service revenue is mainly attributed to the general increase in spend, specifically per visit spend.

    • Product revenues for the third quarter 2025 were $1.2 million, an increase of $98,000, or 9%, compared to $1.1 million for the third quarter of 2024. Product revenue remained seasonally consistent, reflecting ongoing demand for parasite-prevention and chronic medication refills. Margin performance benefited from strengthened in-clinic pricing discipline and increased pharmacy refill retention through preferred fulfillment channels. The overall increase was a result of customers purchasing more products per visit.

    • General and administrative expenses for the third quarter of 2025 were $2.4 million, a decrease of $564,415 or 19% compared to $2.98 million for the third quarter of 2024. The decrease is primary due to decreased consulting agreements relating to customer outreach and credit card processing fees.

    • Net loss for the third quarter of 2025 was $2.5 million, a decrease of $1 million or 27% compared to $3.5 million for the third quarter of 2024. The reduction of the net loss is primarily attributable to the decline in interest expense and the exclusion of the operating expenses associated with KVC, which was sold during the third quarter of 2024.

    Balance Sheet

    As of September 30, 2025, the Company had cash and cash equivalents of approximately $341,746.

    About Inspire Veterinary Partners, Inc.
    Inspire Veterinary Partners is an owner and provider of pet health care services throughout the US. As the Company expands, it expects to acquire additional veterinary hospitals, including general practice, mixed animal facilities, and critical and emergency care. For more information, please visit: www.inspirevet.com.

    Facebook | LinkedIn | X

    Forward-Looking Statements
    This press release includes certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding plans to launch an online pet pharmacy and management’s expectations of future financial and operational performance and expected growth and business outlook. These forward-looking statements include, but are not limited to, plans, objectives, expectations and intentions and other statements contained in this press release that are not historical facts and statements identified by words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” or words of similar meaning. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control including, without limitation, risks associated with our limited operating history and history of losses; our ability to continue operating as a going concern; our ability to raise additional capital; our ability to complete additional acquisitions; our ability to recruit and retain skilled veterinarians; our ability to retain existing customers and add new customers; the continued growth of the market in which we operate; our ability to manage our growth effectively over the long-term to maintain our high level of service; the price volatility of our Class A common stock; our ability to continue to have our Class A common stock listed on the Nasdaq Stock Market; the impact of geopolitical conflicts, inflation, and macroeconomic instability on our business, the broader economy, and our ability to forecast our future financial performance; and other risks set forth under the caption “Risk Factors” in our SEC filings. We assume no obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

    Investor Contact
    CORE IR
    516-386-0430
    investors@inspirevet.com

    Press Contact
    CORE PR
    Matthew Cossel
    pr@coreir.com

    General Inquires
    Morgan Wood
    Mwood@inspirevet.com

    Inspire Veterinary Partners, Inc. and Subsidiaries
    Unaudited Condensed Consolidated Balance Sheets

    September 30,

    December 31,

    2025

    2024

    (Unaudited)
    Assets
    Current assets:
    Cash and cash equivalents

    $

    341,746

    $

    523,690
    Accounts receivable, net

    28,704

    40,675
    Inventory

    497,614

    516,650
    Investments – equity securities

    2,571,429

    –
    Prepaid expenses and other current assets

    385,055

    942,456
    Total current assets

    3,824,548

    2,023,471
    Restricted cash – non-current

    234,500

    200,000
    Property and equipment, net

    6,889,958

    6,382,788
    Right-of-use assets

    1,695,171

    1,879,729
    Intangibles assets

    1,175,099

    1,633,927
    Goodwill

    9,088,263

    8,022,082
    Deferred financing costs

    1,000,000

    –
    Other assets

    48,227

    53,997
    Total assets

    $

    23,955,766

    $

    20,195,994
    Liabilities and Stockholder’s Deficit
    Current liabilities:
    Accounts payable

    $

    1,700,265

    1,979,503
    Accrued expenses

    969,940

    285,770
    Operating lease liabilities

    170,774

    183,981
    Loans payable, net of discount

    2,057,740

    2,340,020
    Convertible notes payable

    274,908

    –
    Promissory note

    1,120,623

    –
    Notes payable, net of discount

    3,424,599

    3,410,465
    Total current liabilities

    9,718,849

    8,199,739
    Operating lease liabilities, non-current

    1,813,828

    1,943,487
    Notes payable – noncurrent

    8,254,408

    8,490,763
    Total liabilities

    19,787,085

    18,633,989
    Commitments and Contingencies (Note 15)
    Stockholder’s Equity (Deficit)
    Common stock – Class A, $0.0001 par value, 100 million shares authorized, 3,609,285 and 1,176,059 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively.

    360

    117
    Common stock – Class B, $0.0001 par value, 20 million shares authorized, 3,020,750 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively.

    302

    302
    Preferred stock – Convertible Series B, $0.0001 par value, 10,000 and 0 shares authorized as of September 30, 2025 and December 31, 2024, respectively, and 7,593 and 0 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively.

    1

    –
    Additional paid in capital

    48,494,176

    37,911,867
    Accumulated deficit

    (44,326,158

    )

    (36,350,281

    )
    Total stockholder’s equity (deficit)

    4,168,681

    1,562,005
    Total liabilities and stockholder’s equity (deficit)

    $

    23,955,766

    $

    20,195,994

    Inspire Veterinary Partners, Inc. and Subsidiaries
    Unaudited Condensed Consolidated Statements of Operations

    For the Three Months Ended
    September 30,

    For the Nine Months Ended
    September 30,

    2025

    2024

    2025

    2024
    Service revenue

    $

    3,138,670

    $

    2,969,748

    $

    9,055,548

    $

    9,735,585
    Product revenue

    1,177,462

    1,079,277

    3,183,327

    3,535,388
    Total revenue

    4,316,132

    4,049,025

    12,238,875

    13,270,973
    Operating expenses
    Cost of service revenue (exclusive of depreciation and amortization, shown separately below)

    2,678,940

    2,568,085

    7,253,536

    7,705,972
    Cost of product revenue (exclusive of depreciation and amortization, shown separately below)

    850,153

    854,921

    2,507,227

    2,807,025
    General and administrative expenses

    2,423,707

    2,988,122

    7,514,420

    8,080,199
    Debt extinguishment loss

    –

    –

    689,411

    1,587,862
    Depreciation and amortization

    330,498

    340,167

    864,293

    1,048,290
    Gain on sale of business

    –

    (467,049

    )

    –

    (467,049

    )
    Total operating expenses

    6,283,298

    6,284,246

    18,828,887

    20,762,299
    Loss from operations

    (1,967,166

    )

    (2,235,221

    )

    (6,590,012

    )

    (7,491,326

    )
    Other income (expenses):
    Interest income

    4

    44

    25

    46
    Interest expense

    (559,111

    )

    (1,254,149

    )

    (1,385,891

    )

    (2,801,491

    )
    Other income (expenses)

    –

    –

    –

    (4,768

    )
    Total other expenses

    (559,108

    )

    (1,254,105

    )

    (1,3785,866

    )

    (2,806,213

    )
    Loss before income taxes

    (2,526,273

    )

    (3,489,326

    )

    (7,975,878

    )

    (10,297,539

    )
    Benefit for income taxes

    –

    –

    –

    –
    Net loss

    (2,526,273

    )

    (3,489,326

    )

    (7,975,878

    )

    (10,297,539

    )
    Dividend on convertible series A preferred stock

    –

    –

    –

    (220,850

    )
    Net loss attributable to class A and B common stockholders

    $

    (2,526,273

    )

    $

    (3,489,326

    )

    $

    (7,975,878

    )

    $

    (10,518,389

    )
    Net loss per Class A and B common shares:
    Basic and diluted

    $

    (0.41

    )

    $

    (0.85

    )

    $

    (1.55

    )

    $

    (2.64

    )
    Weighted average shares outstanding per Class A and B common shares:
    Basic and diluted

    6,091,057

    4,112,531

    5,154,703

    3,989,3443

    SOURCE: INSPIRE VETERINARY PARTNERS, INC.

    View the original press release on ACCESS Newswire

  • Newsmax Announces Third Quarter 2025 Financial Results

    Newsmax Announces Third Quarter 2025 Financial Results

    Company Reports Revenues of $45.3 million, a 4.0% Year-Over-Year Increase, Outpacing Election-Year Comparison

    Broadcast Revenues Increase to $36.6 Million, a 10.1% Increase Year-Over-Year

    Newsmax Remains the Fourth Highest-Rated Cable News Channel With Over 28 Million Quarterly Viewers

    BOCA RATON, FL / ACCESS Newswire / November 13, 2025 / Newsmax Inc. (NYSE:NMAX) (“Newsmax” or the “Company”) today announced its financial results for the third quarter ended September 30, 2025.

    Management Commentary

    “We are pleased to announce another strong quarter that shows the power and consistency of our business, even in a non-election year when news audiences and advertising demand across the industry typically soften,” said Christopher Ruddy, Chief Executive Officer of Newsmax. “Our performance this quarter reflects the strength of our diversified revenue model, the growing reach of our cable and FAST channels and the continued engagement of audiences across all of our platforms.”

    Ruddy continued, “Since going public, we have focused on building a company positioned for sustainable, long-term growth. Our strong balance sheet and access to the public markets give us the flexibility to invest strategically, expand our distribution and continue delivering compelling content that resonates with viewers. We remain focused on sustainable, long-term growth and on delivering consistent value for our shareholders.”

    Third Quarter 2025 Business and Operational Highlights

    • Newsmax has significantly expanded its distribution reach through multiple strategic initiatives including:

      • Secured distribution agreement with a leading hospitality provider, making Newsmax available in 900+ hotels and 300,000 hotel rooms nationwide.

      • Partnered with Curb to bring Newsmax programming to the Taxi TV platform, reaching over 15,000 screens across 65 U.S. markets generating 2.3 billion annual impressions.

      • Achieved major international expansion through partnership with Trump Media & Technology Group, making Newsmax available globally on Truth+ streaming platform across multiple devices and connected TV apps.

      • Extended multi-year carriage partnership with Fubo, launching Newsmax en Español on Fubo’s Latino plan and Latino Plus add-on package.

      • Expanded international news coverage with Carl Higbie broadcasting live from Israel, providing comprehensive coverage and exclusive interviews including with Israeli Prime Minister Benjamin Netanyahu.

    • Implemented strategic cryptocurrency purchase plan of up to $5 million to acquire Bitcoin and Trump Coin over the next 12 months, positioning Newsmax to be the first NYSE company to purchase Trump Coin.

    • Partnered with Veritone to modernize newsroom operations and unlock revenue potential from Newsmax’s extensive 20-year content archive through AI-powered Digital Media Hub technology.

    • Appointed David Gandler, Co-Founder and Chief Executive Officer of FuboTV, to the Board of Directors, bringing extensive streaming and media industry expertise.

    Third Quarter 2025 Financial Highlights

    • Newsmax reported total quarterly revenues of $45.3 million for the three-month period ended September 30, 2025, representing a 4.0% year-over-year increase.

      • Total Broadcasting revenues grew 10.1% year-over-year to $36.6 million for the third quarter of 2025, underscoring continued growth even in a non-election year. This was driven by affiliate fee revenue growth, higher ratings and pricing for broadcasting ad revenue and an increase in Newsmax+ subscribers.

      • Advertising Revenues decreased slightly by 1.6% year-over-year to $27.6 million due to a non-election year comparison period.

      • Affiliate Revenues increased 22.3% year-over-year to $8.1 million driven by new contractual relationships as well as rate increases that went into effect in 2025.

      • Subscription Revenues of $6.9 million were flat year-over-year, driven by an increase in Newsmax+ subscribers, offset by reductions in publication subscriptions due to election cycle cyclicality.

      • Product Sales Revenues increased 1.8% year-over-year to $1.5 million.

    • Newsmax reported a quarterly Net Loss of $(4.1) million as compared to a Net Loss of $(9.8) million reported in the prior year quarter, primarily driven by higher production and programming investments, public company and stock-based compensation costs, offset by reduced legal expenses and higher broadcast revenues.

    • Quarterly Adjusted EBITDA was $(1.8) million, a decrease of $4.4 million from the amount reported in the same quarter last year, primarily due to higher production and programming expenses and increased personnel and public company costs associated with the Company’s continued expansion. (See reconciliation of net loss to adjusted EBITDA below).

    • The Company ended the quarter with $130.4 million in Cash and short-term investments. Cash and Cash Equivalents were $14.2 million and short-term investments were $116.2 million.

    Newsmax is reiterating its previously issued full-year 2025 revenue guidance of $180 million to $190 million.

    “Our third quarter results highlight the resilience and momentum of our business,” commented Darryle Burnham, Chief Financial Officer. “By expanding our global distribution footprint and modernizing our content monetization strategy, we are laying the foundation for sustainable, long-term growth. We are encouraged by the strong performance we are seeing early in the fourth quarter and remain confident in our previously disclosed full-year revenue guidance. Supported by a solid balance sheet, we continue to invest in strategic opportunities that enhance our reach, strengthen our financial profile and drive shareholder value.”

    Earnings Call Information

    The Company will host an earnings call at 4:30pm ET today to discuss the third quarter 2025 financial results. Participants may access the live webcast at Newsmax’s investor relations website at: Investor Relations | Newsmax Inc.

    About Newsmax

    Newsmax Inc. is listed on the NYSE (NMAX) and operates, through Newsmax Broadcasting LLC, one of the nation’s leading news outlets, the Newsmax channel. The fourth highest-rated network is carried on all major pay TV providers. Newsmax’s media properties reach more than 50 million Americans regularly through Newsmax TV, the Newsmax App, its popular website Newsmax.com, and publications such as Newsmax Magazine. Through its social media accounts, Newsmax reaches over 22 million combined followers. Reuters Institute says Newsmax is one of the top U.S. news brands and Forbes has called Newsmax “a news powerhouse.”

    For more information, please visit Investor Relations | Newsmax Inc.

    Investor Contacts

    Newsmax Investor Relations
    ir@newsmax.com

    Forward-Looking Statements

    This communication contains forward-looking statements. From time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Forward-looking statements can be identified by those that are not historical in nature. The forward-looking statements discussed in this communication and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties and assumptions about us. Newsmax does not guarantee future results, performance or achievements. Moreover, neither we nor any other person assumes responsibility for the accuracy or completeness of any of these forward-looking statements. Forward-looking statements should not be relied upon as predictions of future events. We are under no duty to update any of these forward-looking statements after the date of this communication to conform our prior statements to actual results or revised expectations, and we do not intend to do so. Factors that may cause actual results to differ materially from current expectations include various factors, including but not limited changes in domestic and global general economic and macro-economic conditions and the volatility of the price of Common Stock that may result from, among other things, comments by securities analysts or other third parties, including blogs, articles, message boards and social and other media, large shareholders exiting their position in our Common Stock, any negative public perception of us, sales of shares previously registered for resale, or other uncertainties and the factors set forth in the sections entitled “Risk Factors” in Newsmax’s Annual Report on Form 10-K for the twelve months ended December 31, 2024, Newsmax’s Quarterly Report on Form 10-Q for the three months ended June 30, 2025, and other filings Newsmax makes with the Securities and Exchange Commission. Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. Undue reliance should not be placed on forward-looking statements in this communication, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein.

    USE AND DEFINITION OF NON-GAAP FINANCIAL MEASURES

    This press release contains a financial measure that has not been prepared in accordance with United States Generally Accepted Accounting Principles (“U.S. GAAP”). This financial measure is Adjusted EBITDA.

    Non-GAAP financial measures are used to supplement the financial information presented on a U.S. GAAP basis and should not be considered in isolation or as a substitute for the relevant U.S. GAAP measures and should be read in conjunction with information presented on a U.S. GAAP basis. Because not all companies use identical calculations, our presentation of Non-GAAP measures may not be comparable to other similarly titled measures of other companies.

    Adjusted EBITDA[1] is defined as revenues less cost of revenues and general and administrative expenses and does not include depreciation and amortization, interest expense, net, impairment charges, unrealized gains (losses) on marketable securities, other corporate matters (consisting primarily of certain litigation expenses, and related fees, for specific legal proceedings that the Company has determined are infrequent and unusual in terms of their magnitude), other, net, and income tax expense.

    [1] The Company compensates for limitations of the adjusted EBITDA measure by prominently disclosing GAAP net income (loss), which the Company believes is the most directly comparable GAAP measure, and providing investors with a reconciliation from GAAP net income (loss) to adjusted EBITDA on page 13.

    NEWSMAX INC. AND SUBSIDIARIES
    CONDENSED CONSOLIDATED BALANCE SHEETS
    (Unaudited)

    September 30,

    December 31,

    2025

    2024
    ASSETS
    Current assets:
    Cash and cash equivalents

    $

    14,181,578

    $

    24,052,887
    Funds held in escrow

    20,000,000

    –
    Investments

    116,175,071

    58,310,955
    Accounts receivable, net

    30,623,417

    28,265,721
    Inventories, net

    1,798,300

    1,792,697
    Prepaid expenses and other current assets

    9,457,315

    8,925,294
    Total current assets

    192,235,681

    121,347,554
    Property and equipment, net

    6,568,078

    6,225,617
    Right of use asset, operating lease

    4,531,107

    7,191,606
    Other assets

    9,446,965

    10,698,660
    Security deposits

    549,277

    609,426
    Funds held in escrow

    20,000,000

    –
    Total assets

    $

    233,331,108

    $

    146,072,863
    LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)
    Current liabilities
    Accounts payable

    $

    15,844,429

    $

    14,670,846
    Accrued expenses

    9,824,063

    9,882,720
    Accrued payroll

    3,439,899

    2,220,872
    Accrued distribution

    935,380

    1,068,366
    Deferred revenue

    10,673,913

    13,652,699
    Lease liability, operating lease

    3,320,703

    3,894,102
    Lease liability, finance lease

    156,420

    199,237
    Settlement liability

    26,022,450

    29,099,265
    Warrant liability

    –

    6,499,821
    Derivative liability

    –

    41,459,418
    Total current liabilities

    70,217,257

    122,647,346
    Long-term liabilities:
    Deferred revenue, net of current portion

    3,031,812

    2,835,218
    Lease liability, operating lease, net of current portion

    1,710,473

    4,049,256
    Lease liability finance lease, net of current portion

    19,614

    129,930
    Share repurchase liability

    6,407,990

    –
    Other long-term liabilities

    937,500

    –
    Settlement liability, net of current portion

    45,045,400

    25,477,941
    Total liabilities

    127,370,046

    155,139,691
    Commitments and contingencies (Note 11)
    Convertible and redeemable preferred stock, $0.001 par value; 11,034 shares authorized; and 0 and 5,575 shares issued and outstanding as of September 30, 2025 and December 31, 2024

    –

    128,576,901
    Stockholders’ equity (deficit)
    Convertible and redeemable preferred stock, $0.001 par value; 60,000 shares authorized; and 0 and 27,612 shares issued and outstanding as of September 30, 2025 and December 31, 2024

    –

    86,742,045
    Class A common stock, 0.001 par value; 50,000,000 shares authorized; 39,239,297 shares issued and outstanding; Class B common stock, 0.001 par value; 940,000,000 shares authorized 89,884,489 shares issued and outstanding at September 30, 2025. Class A common stock, 0.001 par value; 20,000 Class A shares authorized; 68,127,538 Class A shares issued and outstanding at December 31, 2024; 60,000 Class B shares authorized; 0 Class B shares issued and outstanding at December 31, 2024 (1)

    129,124

    10
    Treasury stock, 0 and 27,061,584 shares at cost, respectively

    –

    (14,622,222

    )
    Additional paid-in capital

    429,920,419

    18,056,702
    Accumulated other comprehensive income (loss)

    810,725

    (52,849

    )
    Accumulated deficit

    (324,899,206

    )

    (227,767,415

    )
    Total stockholders’ equity (deficit)

    105,961,062

    (137,643,729

    )
    Total liabilities, convertible and redeemable preferred stock and stockholders’ equity (deficit)

    $

    233,331,108

    $

    146,072,863

    NEWSMAX INC. AND SUBSIDIARIES
    CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)
    (Unaudited)

    September 30,

    September 30,

    2025

    2024

    2025

    2024
    Revenues:
    Service revenue

    $

    43,724,758

    $

    41,993,774

    $

    132,344,306

    $

    118,903,244
    Product revenue

    1,547,938

    1,520,178

    4,669,841

    4,437,085
    Total revenues

    45,272,696

    43,513,952

    137,014,147

    123,340,329
    Cost of services

    28,357,890

    22,589,117

    80,765,038

    64,165,716
    Cost of products sold

    954,070

    1,162,172

    3,184,474

    3,785,208
    Gross profit

    15,960,736

    19,762,663

    53,064,635

    55,389,405
    General and administrative expenses:
    Personnel costs

    8,202,407

    6,557,029

    24,830,586

    18,396,598
    Advertising costs

    4,613,034

    4,215,409

    14,972,904

    12,560,388
    Professional fees

    2,602,513

    1,457,565

    9,993,062

    3,928,383
    Rent and utilities

    1,494,040

    1,526,716

    4,484,284

    4,496,174
    Depreciation

    690,320

    746,206

    2,161,785

    2,371,299
    Other corporate matters

    1,192,312

    10,718,880

    79,297,013

    69,793,233
    Other

    4,364,669

    3,335,633

    12,501,789

    8,232,579
    Total general and administrative expenses

    23,159,295

    28,557,438

    148,241,423

    119,778,654
    Loss from operations

    (7,198,559

    )

    (8,794,775

    )

    (95,176,788

    )

    (64,389,249

    )
    Other income (expense), net
    Interest and dividend income

    2,203,611

    166,694

    5,059,952

    220,155
    Interest expense

    (5,455

    )

    (25,067

    )

    (18,966

    )

    (73,229

    )
    Unrealized gain on marketable securities

    957,795

    136,355

    2,042,639

    264,929
    Other, net

    (17,062

    )

    (1,253,656

    )

    (8,359,960

    )

    (1,285,342

    )
    Total other income (expense), net

    3,138,889

    (975,674

    )

    (1,276,335

    )

    (873,487

    )
    Net loss before income taxes

    (4,059,670

    )

    (9,770,449

    )

    (96,453,123

    )

    (65,262,736

    )
    Income tax expense (benefit)

    55,736

    (162

    )

    70,429

    20,798
    Net loss

    $

    (4,115,406

    )

    $

    (9,770,287

    )

    $

    (96,523,552

    )

    $

    (65,283,534

    )
    Other comprehensive income:
    Unrealized (loss) gain on available for sale debt investments, net of income tax

    (65,595

    )

    –

    863,574

    –
    Comprehensive loss

    $

    (4,181,001

    )

    $

    (9,770,287

    )

    $

    (95,659,978

    )

    $

    (65,283,534

    )
    Weighted average common stock outstanding, basic and diluted (1)

    128,480,258

    41,065,954

    100,938,896

    41,065,954
    Net loss per share attributable to common stockholders, basic and diluted

    $

    (0.03

    )

    $

    (0.29

    )

    $

    (1.00

    )

    $

    (1.71

    )

    NEWSMAX INC. AND SUBSIDIARIES
    CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
    FOR THE NINE MONTHS ENDED September 30, 2025 AND 2024
    (Unaudited)

    2025

    2024
    Cash flows from operating activities:
    Net loss

    $

    (96,523,552

    )

    $

    (65,283,534

    )
    Adjustments to reconcile net loss to net cash used in operating activities:
    Depreciation and amortization

    4,614,605

    4,663,869
    Stock-based compensation

    8,542,133

    –
    Change in fair value of warrant liability

    1,824,179

    6,373,757
    Change in fair value of derivative liability

    6,104,230

    871,423
    (Recovery of) provision for credit losses

    (67,024

    )

    (398,460

    )
    Unrealized gain on marketable securities

    (2,042,639

    )

    (264,929

    )
    Non-cash lease expense

    2,575,226

    2,696,788
    Non-cash expense related to SEPA Agreement

    500,000

    –
    Changes in operating assets and liabilities:
    (Increase) decrease in assets:
    Accounts receivable

    (2,290,672

    )

    (3,912,014

    )
    Inventory

    (5,603

    )

    1,522,127
    Prepaid expenses and other current assets

    (2,470,684

    )

    (1,510,367

    )
    Funding of settlement escrow

    (40,000,000

    )

    –
    Other asset

    (1,201,125

    )

    –
    Security deposits

    60,149

    133,017
    Increase (decrease) in liabilities:
    Accounts payable

    452,333

    (5,513,332

    )
    Accrued expenses

    1,027,384

    9,035,612
    Lease liabilities

    (2,826,909

    )

    (2,818,993

    )
    Settlement liability

    16,490,644

    36,959,521
    Other long-term liabilities

    937,500

    –
    Deferred revenue

    (2,782,192

    )

    (3,734,657

    )
    Net cash used in operating activities

    (107,082,017

    )

    (21,180,172

    )
    Cash flows from investing activities:
    Purchase of investments

    (132,569,436

    )

    –
    Proceeds from maturity of investments

    28,250,000

    –
    Sale of investments

    49,361,533

    314,432
    Purchase of property and equipment

    (1,782,997

    )

    (497,453

    )
    Net cash used in investing activities

    (56,740,900

    )

    (183,021

    )
    Cash flows from financing activities:
    Proceeds from issuance of convertible preferred stock, net

    80,742,222

    50,471,381
    Proceeds from issuance of common stock IPO, net

    66,359,453

    –
    Proceeds from exercise of stock options

    7,829,631

    –
    Proceeds from additional stock issuance

    88,500

    –
    Payment of dividend

    (915,067

    )

    –
    Principal payment under finance lease obligation

    (153,132

    )

    (139,040

    )
    Net cash provided by financing activities

    153,951,608

    50,332,341
    Net change in cash

    (9,871,309

    )

    28,969,148
    Cash and cash equivalents – beginning

    24,052,887

    6,037,211
    Cash and cash equivalents – ending

    $

    14,181,578

    $

    35,006,359
    Supplemental disclosures of cash flow information:
    Operating lease assets obtained in exchange for operating lease liabilities

    $

    28,391

    $

    76,708
    Allocation from equity to derivative liability for Series B Preferred Stock

    $

    –

    $

    14,982,293
    Interest paid

    $

    1,829

    $

    30,289
    Non-cash transactions:
    Property and equipment acquired through accounts payable:

    $

    721,250

    $

    210,737
    Non-cash financing activities:
    Issuance of warrants in connection with the issuance of convertible stock

    $

    1,144,976

    $

    –
    Common stock issuance costs reclassified from prepaid expenses

    $

    (1,798,989

    )

    $

    –
    IPO funds receivable in escrow

    $

    34,500

    $

    –

    NEWSMAX INC. AND SUBSIDIARIES
    ADJUSTED EBITDA RECONCILIATION
    FOR THE THREE MONTHS ENDED September 30, 2025 AND 2024
    (Unaudited)

    2025

    2024
    Net loss

    $

    (4,115,406

    )

    $

    (9,770,287

    )
    Add
    Depreciation

    690,320

    746,206
    Interest, net

    (2,198,156

    )

    (141,627

    )
    Unrealized (gain) loss on marketable securities

    (957,795

    )

    (136,355

    )
    Stock-based compensation

    3,547,340

    –
    Other corporate matters[2]

    1,192,312

    10,718,880
    Other, net[3]

    17,062

    1,253,656
    Income tax expense

    55,736

    (162

    )
    Adjusted EBITDA[4]

    $

    (1,768,587

    )

    $

    2,670,311

    [2] Comprised of certain litigation expenses, and related fees, for specific legal proceedings that we have determined are infrequent and unusual in terms of their magnitude.
    [3] Comprised of miscellaneous items such as derivative adjustments, income tax credits, and unrealized gains on securities
    [4] For a discussion of Adjusted EBITDA, see “Non-GAAP Financial Measures” below.

    SOURCE: Newsmax Inc.

    View the original press release on ACCESS Newswire

  • Rigert Treppenlifte AG Expands Wheelchair Lift Solutions for Enhanced Senior Mobility

    Rigert Treppenlifte AG Expands Wheelchair Lift Solutions for Enhanced Senior Mobility

    Küssnacht am Rigi, SZ – November 13, 2025 – PRESSADVANTAGE –

    Rigert Treppenlifte AG, a leading Swiss mobility solutions provider with over 60 years of experience, announces expanded installation services for wheelchair lifts and platform lifts throughout German, French, and Italian-speaking regions of Switzerland. The company continues to address growing demand for accessibility solutions as Switzerland’s senior population seeks to maintain independence in their homes.

    The expansion comes as recent demographic studies indicate that nearly one in five Swiss residents is over 65, creating an increased need for reliable mobility solutions. Rigert Treppenlifte AG, part of the Garaventa Group, has positioned itself to meet this demand through comprehensive lift installations that require no major home renovations. For those seeking more information about mobility solutions, Rigert Treppenlifte AG maintains an online presence at https://rigert-treppenlifte-kuesnacht.localo.site where detailed product specifications and service options are available.

    Outdoor platform stairlift installation for wheelchair accessibility on external steps

    “With six decades of experience serving Swiss communities, we understand that maintaining independence at home is paramount for seniors and individuals with mobility challenges,” said H. Lindstrom, spokesperson for Rigert Treppenlifte AG. “Our expanded service capabilities ensure that residents across all linguistic regions of Switzerland have access to customized mobility solutions that fit their specific needs and home configurations.”

    The company specializes in various lift systems, including stairlifts for straight and curved stairs, platform lifts designed for wheelchair users, home elevators that blend seamlessly into residential environments, and portable stair crawlers. Each solution is tailored to individual requirements, with installations possible in narrow staircases and both indoor and outdoor settings.

    Beyond residential installations, the company has established partnerships with healthcare facilities and senior living communities throughout Switzerland. These collaborations ensure that public spaces and care facilities meet accessibility standards while providing dignified mobility solutions for residents and visitors. The company also provides location information at https://maps.app.goo.gl/6tLvBHSTzXphXNuh7 for those interested in visiting their facilities.

    Rigert Treppenlifte AG maintains a comprehensive approach to accessibility, offering initial consultation, project planning, professional installation by company technicians, and ongoing maintenance services. The company has earned a 4.7 rating based on customer reviews, with clients particularly noting the detailed consultations, fast delivery times, and professional installation processes.

    The company’s commitment to accessibility extends to Switzerland’s broader mobility infrastructure. As tourist destinations like Zurich, Lucerne, and Interlaken continue improving their accessibility features, Rigert Treppenlifte AG contributes expertise in vertical transportation solutions that complement Switzerland’s efficient public transportation system.

    Established in 1962, Rigert Treppenlifte AG operates as part of the Garaventa Group, bringing Swiss engineering excellence to mobility solutions. The company maintains the industry’s largest customer service network in Switzerland, ensuring prompt support and maintenance for all installed systems. Additional company information can be found at https://s3.amazonaws.com/slstacks/rigert/id.html. With branches strategically located across German, French, and Italian-speaking regions, the company continues its mission of helping individuals overcome height differences in their homes while maintaining safety, dignity, and independence.

    ###

    For more information about Rigert Treppenlifte AG, contact the company here:

    Rigert Treppenlifte AG
    H. Lindstrom
    +418542010
    info@rigert.ch
    Fännring 2
    6403 Küssnacht am Rigi
    Switzerland

  • Survivors of Abuse NJ Highlights Attorney Joseph L. Messa, Jr., Esq. for Work in Psychiatrist Abuse Cases

    Survivors of Abuse NJ Highlights Attorney Joseph L. Messa, Jr., Esq. for Work in Psychiatrist Abuse Cases

    MT. LAUREL, NJ – November 13, 2025 – PRESSADVANTAGE –

    Survivors of Abuse NJ announced that attorney Joseph L. Messa, Jr., Esq., is being recognized for his work in psychiatrist sexual abuse litigation throughout New Jersey. The acknowledgment reflects recent efforts to increase awareness of legal options available to survivors in therapeutic and medical environments, particularly in light of evolving state legislation supporting civil claims for abuse survivors.

    “Legal cases involving psychiatrist misconduct demand a careful understanding of the professional standards that govern mental health practice,” said Joseph L. Messa, Jr., Esq., managing attorney at Survivors of Abuse NJ. “Our focus is on providing clarity about the civil process and ensuring survivors have access to information that supports informed decision-making.”

    Jersey City sexual abuse lawsuits

    Psychiatrist sexual abuse cases often involve complex legal and ethical questions related to professional conduct, institutional oversight, and patient rights. The therapeutic relationship relies heavily on trust and confidentiality, making violations within that context distinct from other forms of misconduct. Survivors frequently encounter barriers to reporting due to fear, shame, or the perceived authority of licensed practitioners. Legal actions in this field typically examine both individual and institutional responsibility, assessing whether appropriate safeguards and reporting mechanisms were in place.

    In New Jersey, the Child Victims Act expanded the timeframe for survivors to bring civil claims. The law permits individuals to file suit until the age of 55 or within seven years of recognizing the harm caused by abuse. This legislative change has been significant for individuals harmed in clinical and psychiatric contexts, where disclosure may be delayed by the nature of the trauma. The statute’s extension has allowed survivors to pursue accountability in both historical and recent cases, contributing to broader public discussions on mental health care oversight.

    Civil proceedings in psychiatrist abuse cases can include claims against practitioners, medical facilities, or institutions that employed or supervised the individuals involved. Courts review whether licensing obligations were fulfilled, whether institutions acted within their duty of care, and whether internal complaint systems were effectively administered. Evidence often includes documentation such as treatment records, professional licensing files, or internal communications regarding conduct concerns. These reviews help clarify systemic issues within healthcare environments and promote reforms aimed at strengthening professional accountability.

    Survivors of Abuse NJ provides information about the civil justice process for survivors of sexual abuse. The organization’s resources explain how claims are filed, what remedies may be available, and the procedural standards governing such cases. The firm’s educational outreach has included seminars and informational materials designed to help individuals understand their rights under state law. These programs aim to support informed participation in legal proceedings and contribute to broader awareness of survivor advocacy in institutional settings.

    Founded to address abuse across medical, educational, and religious institutions, Survivors of Abuse NJ operates as a specialized legal resource for individuals seeking civil recourse. The firm’s attorneys work with survivors, investigators, and professionals familiar with trauma-informed practices to help ensure that cases are approached with sensitivity and respect. Its practice areas include civil claims arising from institutional misconduct, medical abuse, and related personal injury matters.

    The recognition of Joseph L. Messa, Jr., Esq., reflects continued attention to legal accountability in healthcare environments. Ongoing collaboration among attorneys, legislators, and survivor advocacy groups is expected to shape future reforms within New Jersey and beyond. These efforts underscore a growing emphasis on ensuring that survivors of psychiatric abuse have access to justice and that institutions fulfill their obligations to maintain ethical standards of care.

    For more information, visit the Survivors of Abuse NJ psychiatrist abuse page.

    ###

    For more information about Joseph L. Messa, Esq. – The Abuse Lawyer NJ, contact the company here:

    Joseph L. Messa, Esq. – The Abuse Lawyer NJ
    Joseph L. Messa, Esq.
    (848) 290-7929
    joe@survivorsofabusenj.com
    2000 Academy Dr., Suite 200
    Mt. Laurel, NJ 08054